Erythropoietin muteins with enhanced activity

摘要

Novel modifications of erytropoietin (Epo) which improve the biological activity of the protein are provided. The modified Epo proteins (Epo muteins) may be used in the same manner as has been demonstrated for wild type Epo, except that relatively smaller doses are required due to the enhanced biological activity. Methods of using the Epo muteins for treatment of blood disorders are provided. A method of obtaining additional Epo muteins with enhanced biological activity is also provided.